Workflow
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
ACADACADIA Pharmaceuticals(ACAD) ZACKS·2025-02-26 23:25

Core Viewpoint - Acadia Pharmaceuticals reported quarterly earnings of 0.17pershare,missingtheZacksConsensusEstimateof0.17 per share, missing the Zacks Consensus Estimate of 0.19 per share, and showing a decline from 0.28pershareayearago,indicatinganearningssurpriseof−10.530.28 per share a year ago, indicating an earnings surprise of -10.53% [1] Financial Performance - The company posted revenues of 259.6 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.79%, compared to 231.04millioninthesamequarterlastyear[2]−Overthelastfourquarters,AcadiahasexceededconsensusEPSestimatesthreetimesandhastoppedconsensusrevenueestimatesthreetimesaswell[2]StockPerformance−Acadiashareshaveincreasedbyapproximately3.6231.04 million in the same quarter last year [2] - Over the last four quarters, Acadia has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - Acadia shares have increased by approximately 3.6% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is 0.14 on revenues of 235.58million,andforthecurrentfiscalyear,itis235.58 million, and for the current fiscal year, it is 0.76 on revenues of $1.04 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]